| Information Item | Value |
|---|---|
| Dataset Name | Mar: Rosetta datasets |
| Dataset Number | 1 |
| Short Description | 7 conditions (plus 4 repeats of wt, 1 of cna1cna2, 1 of his3) |
| Source URL | http://www.rii.com/ |
| Reference | Matthew J. Marton et al., Nature Medicine 4: 1293-1301 (1998) |
| Strains | various mutations of 'wild type', strain table lists strains used as YPH499, R563, R558, R567, MCY300, R132, R133, R559, BY4719, BY4738, R491, BY4728, BY4729, R1226 |
| Conditions | YPD + 0.004% adenine wt vs. cna1cna2 wt vs. wt + 1 ug/ml FK506 cna1cna2 vs. cna1cna2 + 1 ug/ml FK506 wt vs. wt + 50 ug/ml FK506 wt vs. wt + 10 mM 3AT his3 vs. his3 + 10 mM 3AT wt vs. his3 |
| Date Added to ExpressDB | Feb 4 1999 3:03:18:726PM |
| Number of Measures on ExpressDB | 42 (here to download dataset and view measure details) |
| Long Description | Paper abstract - We describe here a method for drug target validation and identification of secondary drug target effects based on genome-wide gene expression patterns. The method is demonstrated by several experiments, including treatment of yeast mutant strains defective in calcineurin, immunophilins or other genes with the immunosuppressants cyclosporin A or FK506. Presence or absence of the characteristic drug 'signature' pattern of altered gene expression in drug-treated cells with a mutation in the gene encoding a putative target established whether that target was required to generate the drug signature. Drug dependent effects were seen in 'targetless' cells, showing that FK506 affects additional pathways independent of calcineurin and the immunophilins. The described method permits the direct confirmation of drug targets and recognition of drug-dependent changes in gene expression that are modulated through pathways distinct from the drug's intended target. Such a method may prove useful in improving the efficiency of drug development programs. |
Please contact Wayne Rindone for more information, or with any questions, comments, or concerns.
Copyright (c) 2006 by Wayne Rindone and the President and Fellows of Harvard University